Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Michigan

Sites in Ann Arbor, MI

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1234
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Michigan, Ann Arbor, MI
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Michigan, Ann Arbor, MI. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 85–96 of 1,234 matching trials with a site at University of Michigan, Ann Arbor, MI.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Not yet recruiting Phase 2 Interventional

Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC

NCT07870746
Site status not listed — check the official record
View directory record Official record
Conditions
ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic, Renal Cell Cancer, Recurrent, Clear Cell Renal Cell Cancer (ccRCC)
Interventions
177Lu-TLX250
Drug
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Duarte, California • San Diego, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:40 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690
Site status not listed — check the official record
View directory record Official record
Conditions
Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Interventions
Bel-sar, Suprachoroidal Microinjector, Infrared Laser, Sham Infrared Laser, Sham Microinjector
Drug · Device
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
25
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional

EPPIC: Easing Pelvic Pain Interventions Clinical Research Program

NCT05127616
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Urologic Chronic Pelvic Pain Syndrome (UCPPS), Interstitial Cystitis, Bladder Pain Syndrome, Chronic Prostatitis, Chronic Pain, Chronic Pelvic Pain Syndrome, Chronic Overlapping Pain Disorders
Interventions
Minimal Contact-Cognitive Behavior Therapy, Patient Education/Support
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:40 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118
Site status not listed — check the official record
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:40 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

NCT07644559
Status at this site: Recruiting
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
Interventions
VS-7375, cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
25
States / cities
Los Angeles, California • Jacksonville, Florida • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:40 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Investigating Near-Threshold Perception During Ultrasonic Deep Brain Stimulation

NCT07840521
Site status not listed — check the official record
View directory record Official record
Conditions
Consciousness, Level Altered
Interventions
Low-intensity focused ultrasound pulsation (LIFUP), Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy, Multi-modal glymphatic function MRI
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 40 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:40 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801
Status at this site: Recruiting
View directory record Official record
Conditions
Crohn's Disease
Interventions
IV Tulisokibart, SC Tulisokibart, IV Placebo, SC Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
87
States / cities
Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:40 PM EDT
Active, not recruiting Phase 3 Interventional

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT04822181
Site status not listed — check the official record
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
130
States / cities
Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:40 PM EDT
Recruiting Phase 3 Interventional

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

NCT03588975
Status at this site: Recruiting
View directory record Official record
Conditions
Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of Knee
Interventions
MACI, microfracture
Biological · Procedure
Lead sponsor
Vericel Corporation
Industry
Eligibility
10 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
14
States / cities
Palo Alto, California • Sacramento, California • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:40 PM EDT
Recruiting Phase 2 Interventional

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

NCT04302025
Status at this site: Recruiting
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
Drug · Procedure
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
38
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:40 PM EDT
Recruiting Phase 1Phase 2 Interventional

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

NCT04643002
Status at this site: Recruiting
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:40 PM EDT
Recruiting Phase 1 Interventional

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

NCT07199465
Status at this site: Recruiting
View directory record Official record
Conditions
Cytomegalovirus Prophylaxis
Interventions
Letermovir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:40 PM EDT

About this University of Michigan institution page

What this page lists
ClinicalTrials.gov records that list University of Michigan in Ann Arbor, MI as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.